Literature DB >> 25944303

Reduced doses of cladribine and cytarabine regimen was effective and well tolerated in patients with refractory-risk multisystem Langerhans cell histiocytosis.

Diego A Rosso1,2,3, Diego Amaral4, Antonio Latella5, Guillermo Chantada6, Jorge L Braier6.   

Abstract

Entities:  

Keywords:  Langerhans cell histiocytosis; cladribine; cytarabine; reduced doses; refractory/progressive risk organ multisystem; salvage therapy

Mesh：

Substances：

Year:  2015        PMID： 25944303     DOI： 10.1111/bjh.13475

Source DB:  PubMed          Journal:  Br J Haematol        ISSN： 0007-1048            Impact factor:   6.998


× No keyword cloud information.
  3 in total

1.  Cladribine and cytarabine in refractory multisystem Langerhans cell histiocytosis: results of an international phase 2 study.

Authors:  Jean Donadieu; Frederic Bernard; Max van Noesel; Mohamed Barkaoui; Odile Bardet; Rosella Mura; Maurizio Arico; Christophe Piguet; Virginie Gandemer; Corinne Armari Alla; Niels Clausen; Eric Jeziorski; Anne Lambilliote; Sheila Weitzman; Jan Inge Henter; Cor Van Den Bos
Journal:  Blood       Date:  2015-07-20       Impact factor: 22.113

Review 2.  Targeting the Adaptive Immune System in Depression: Focus on T Helper 17 Cells.

Authors:  Eléonore Beurel; Eva M Medina-Rodriguez; Richard S Jope
Journal:  Pharmacol Rev       Date:  2022-04       Impact factor: 25.468

3.  Vemurafenib provides a rapid and robust clinical response in pediatric Langerhans cell histiocytosis with the BRAF V600E mutation but does not eliminate low-level minimal residual disease per ddPCR using cell-free circulating DNA.

Authors:  Dmitry Evseev; Irina Kalinina; Elena Raykina; Daria Osipova; Zalina Abashidze; Anna Ignatova; Anna Mitrofanova; Alexey Maschan; Galina Novichkova; Michael Maschan
Journal:  Int J Hematol       Date:  2021-08-12       Impact factor: 2.490
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.